Device
MR-001
MR-001 is a medical device with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
40%
Ph not_applicable
3
60%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
N/ANon-phased studies
3(60.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (40.0%)
N/A3 (60.0%)
Trials by Status
completed360%
not_yet_recruiting120%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
completednot_applicable
Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation
NCT06051539
recruitingphase_1
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
NCT07235202
completednot_applicable
Facilitators and Barriers to the Clinical Implementation of MR-001
NCT06003790
not_yet_recruitingphase_1
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
NCT06134531
completednot_applicable
Post-Stroke Walking Speed and Community Ambulation Conversion Study
NCT04121754
Clinical Trials (5)
Showing 5 of 5 trials
NCT06051539Not Applicable
Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation
NCT07235202Phase 1
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
NCT06003790Not Applicable
Facilitators and Barriers to the Clinical Implementation of MR-001
NCT06134531Phase 1
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
NCT04121754Not Applicable
Post-Stroke Walking Speed and Community Ambulation Conversion Study
All 5 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 5